WGS Dhuwit awis perusahaan genedx.com

Logo grafis genedx.com (WGS)

High barriers to entry, driven by its IT platform and stringent CLIA standards, define the financial stability of GeneDx Holdings Corp. (WGS). Cash reserve dynamics demonstrate current liquidity, where 0.17 reflects the latest metric value. A steady order flow across US laboratories confirms the demand for precision medicine, while technological superiority in diagnosing rare pathologies allows the company to confidently maintain its market leadership.

WGS - Dhuwit awis perusahaan Sema4 ing rentang 28.04.2023 - 21.11.2026

Rincian metrik keuangan lan pasar GeneDx Holdings (WGS)

- nilai saham lan prakiraan konsensus rega:
Pambiji fundamental perusahaan:genedx.com WGS
Produk mawa merek GeneDx

This metric measures the total volume of liquid assets on the balance sheet, determining the business's ability to cover operating expenses without seeking external financing. Analyzing the level of cash reserves allows for an assessment of capital deficiency risk, which is critically important for GeneDx Holdings Corp. (WGS), as maintaining laboratories requires significant investment until high margins are achieved through database scaling.

Pesaing utama

Volume dana dhuwit perusahaan TEM|QGEN - Cadangan dhuwit perusahaan|ionispharma.com - Dhuwit awis perusahaan|Sisa dhuwit perusahaan RGEN|Avidity Corp - Volume dana dhuwit perusahaan|CRISPR Therapeutics Corp - Gunggung dana dhuwit perusahaan|RARE: Volume dana dhuwit perusahaan|BEAM - Aset likuid perusahaan|SRPT (Sarepta Therapeutics) - Volume dana dhuwit perusahaan|Dhuwit awis perusahaan Twist Bioscience Inc (TWST)|Volume dana dhuwit perusahaan TXG|Aset likuid perusahaan Intellia|Stoke - Dhuwit awis perusahaan|BLFS: Dhuwit awis lan setara dhuwit awis perusahaan|Wave Life Sciences Corp - Volume dana dhuwit perusahaan|Maze Therapeutics, Inc. (MAZE) - Dhuwit awis perusahaan|Sionna Therapeutics Inc (SION) - Dana dhuwit perusahaan|Dhuwit awis perusahaan Prime Medicine Corp|Dana dhuwit perusahaan tayshagtx.com|QURE - Posisi dhuwit perusahaan|Dhuwit awis perusahaan MGTX (MeiraGTx Holdings plc)|REGENXBIO (RGNX) - Posisi dhuwit perusahaan|Volume dana dhuwit perusahaan SLDB (Solid Biosciences Inc.)|Sisa dhuwit perusahaan OCGN|PacBio Corp - Volume dana dhuwit perusahaan|Benitec Biopharma Inc. (BNTC) - Dhuwit awis perusahaan|DSGN: Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan RCKT|Dhuwit awis perusahaan FDMT|Dhuwit awis lan setara dhuwit awis perusahaan LXEO (Lexeo Therapeutics)|Volume dana dhuwit perusahaan KRRO|Editas Medicine, Inc. - Dhuwit awis lan setara dhuwit awis perusahaan|Dana dhuwit perusahaan Silence Therapeutics Inc. SLN|Volume dana dhuwit perusahaan ProQR Therapeutics N.V. PRQR|CDXS: Dhuwit awis perusahaan|Posisi dhuwit perusahaan Sangamo (SGMO)|NAUT (Nautilus Bio) - Dhuwit awis perusahaan|MGX - Aset likuid perusahaan|DTIL (Precision BioSciences Inc.) - Volume dana dhuwit perusahaan|generationbio.com (GBIO) - Aset likuid perusahaan|Dana dhuwit perusahaan Boundless Bio Inc (BOLD)|Volume dana dhuwit perusahaan Exicure Inc. (XCUR)|Dana dhuwit perusahaan imunon.com IMNN|Volume dana dhuwit perusahaan Phio Pharmaceuticals PHIO|Mustang Bio Inc - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan transcodetherapeutics.com|BNGO: Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan APDN|BLUE (bluebirdbio.com) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan ImmunoPrecise Antibodies IPA|Dhuwit awis perusahaan OMGA (omegatherapeutics.com)|Volume dana dhuwit perusahaan Singular Genomics Systems, Inc. (OMIC)|Volume dana dhuwit perusahaan RGLS (Regulus Therapeutics, Inc.)|Volume dana dhuwit perusahaan Syros SYRS|Telesis Bio, Inc. - Volume dana dhuwit perusahaan|TRACON Pharmaceuticals (TCON) - Dhuwit awis perusahaan|UBX: Volume dana dhuwit perusahaan